Skip to main content

NeuroMusculoskeletal Institute

Research and Grants

Physicians and researchers at the Rowan-Virtua NeuroMusculoskeletal Institute (NMI), an integrated pain management and substance use disorder (SUD) institute, are deeply involved in investigations and clinical research trials that target advancements in prevention, treatment, harm reduction, and recovery. Most of the NMI's patient population has a long-standing relationship with our clinical practice, offering us the ability to easily connect a large, diverse patient population to clinical research trials and advancements.

The NMI works closely with the Rowan–Virtua School of Osteopathic Medicine (Rowan–Virtua SOM) Clinical Trials Department, which is conveniently located in the same academic building in Stratford, NJ. The Rowan–Virtua SOM Clinical Trials Department acts as an in-house contract research organization, providing 24-hour support.

The NMI is designated by the State of New Jersey as the Southern NJ MAT Center of Excellence (SNJMATCOE). As recipient of a $2 million annual award from the New Jersey Division of Human Services (DHS) and Division of Medical Assistance and Health Services (DMAHS), the SNJMATCOE plans, creates, and executes statewide training content, education, and mentoring initiatives. Richard Jermyn, DO, FAAPMR, Professor and Hunterdon Health Endowed Chair of the NMI, serves as the SNJMATCOE Principal Investigator (PI).

Research efforts of Richard Jermyn, DO, FAAPMR

Dr. Jermyn's research efforts to date have netted more than $25 million in state and federal funding, most notably funding to educate all licensees utilizing standardized, evidence-based curricula and content on the appropriate prescription of opioids and SUD treatment. Below are some of the NMI's current sponsored research initiatives.

Co-Principal Investigator, Enhancing First Responder Access to Overdose Treatment in Atlantic County, New Jersey, $2,000,000 over four years, September 2019.

Principal Investigator, Minority AIDS Initiative for High Risk Men of New Jersey, $2,500,000 over five years, August 2019.

Principal Investigator, the New Jersey Opioid Medical Education Program (NJ–OMEP,) $941,582.31 over one year, April 2019 (renewed each year).

Principal Investigator, Southern New Jersey Medication for Addiction Treatment Center of Excellence (SNJ–MATrx–COE), $2,000,000 over one year, March 2019 ($2,000,000 renewed each year).

Principal Investigator, Southern New Jersey Medication for Addiction Treatment Center of Excellence (SNJ–MATrx–COE) Training Amendment, $500,000 over one year, October 2022.

Principal Investigator, Buprenorphine Training Course, SAMHSA, $1,000,000 over one year, March 2019.

Principal Investigator, A Naloxone Training Curriculum for Patients with Opiate Use Disorders to Prevent Fatal Overdose, New Jersey Health Foundation, Grant #PC 46–19, $35,000 over one year, February 2019.

Principal Investigator, New Jersey Collaborative to Improve Access to Overdose Treatment, SAMHSA, $923,340 over five years, August 2018.

Principal Investigator, Opioid Education for Oral Health Workforce and Dental Students Program, HRSA, $500,000 over five years, July 2018.

Principal Investigator, American Osteopathic Association Cost Effectiveness of OMT, $340,468 over two years, May 2018.

Principal Investigator, New Jersey Opioid Medical Education Program (STORI GRANT), $219,561 over two years, January 2018.

Principal Investigator, New Jersey Geriatrics Workforce Enhancement Program—Opioid Supplemental Funding, July 1, 2018.

Principal Investigator, Swedish Lottery Award, $100,000 for a music therapy program, ongoing.